hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The Scottish Government backs plans to bar dual mandates – MSPs who also sit as MPs or members of the House of Lords – from sitting at Holyrood after the 2026 Scottish Parliament election. 11 December – The Scottish Government announces that Scotland will follow the UK's permanent ban on the use of puberty blockers for under-18s questioning their gender. 12 December – Catholic priest Father Daniel Doherty is sentenced to 16 months in prison after sexually assaulting a sleeping man on a train to Edinburgh. 13 December – The Glasgow South Western Line is closed between Carlisle and Gretna after a HGV crashes off the A74(M) motorway onto the railway line near Gretna; the driver is arrested and charged over the incident. 14 December – Seven people are taken to hospital for treatment, with one man in a critical condition, after the roof of a double-decker bus is torn off when it collides with a railway bridge in Glasgow City Centre after taking a wrong turn. 15 December – Violence and disorder breaks out in Glasgow city centre ahead of the Scottish League Cup final between Celtic and Rangers at Hampden Park. An IT issue forces flights at Edinburgh Airport to be suspended for several hours. 17 December – MSPs vote unanimously in favour of plans to ban dual mandates. Following an external review into the use of messaging services, Deputy First Minister Kate Forbes announces that Scottish Government ministers and staff will be banned from using WhatsApp for official business.
The human musculoskeletal system (also known as the human locomotor system, and previously the activity system) is an organ system that gives humans the ability to move using their muscular and skeletal systems. The musculoskeletal system provides form, support, stability, and movement to the body. The human musculoskeletal system is made up of the bones of the skeleton, muscles, cartilage, tendons, ligaments, joints, and other connective tissue that supports and binds tissues and organs together. The musculoskeletal system's primary functions include supporting the body, allowing motion, and protecting vital organs. The skeletal portion of the system serves as the main storage system for calcium and phosphorus and contains critical components of the hematopoietic system. This system describes how bones are connected to other bones and muscle fibers via connective tissue such as tendons and ligaments. The bones provide stability to the body. Muscles keep bones in place and also play a role in their movement. To allow motion, different bones form joints together. Cartilage prevents the bone ends from rubbing directly onto each other. Muscles contract to move the bones attached at the joint. The joints and muscles are designed to interact harmoniously so that any applied muscular force keeps the joint positioned and aligned correctly during movement and this, reciprocally, helps to maintain the correct length and tension in those corresponding muscles. There are, however, diseases and disorders that may adversely affect the function and overall effectiveness of the system.
=== Optics === The merger of microfluidics and optics is typical known as optofluidics. Examples of optofluidic devices are tunable microlens arrays and optofluidic microscopes. Microfluidic flow enables fast sample throughput, automated imaging of large sample populations, as well as 3D capabilities, or superresolution.
In 2015, Xi's administration oversaw the establishment of two circuit courts under the Supreme People's Court, followed by four other circuit courts being established in 2016. Hangzhou Internet Court was established as a court of special jurisdiction in 2017, followed by the establishment of Beijing Internet Court and Guangzhou Internet Court. Shanghai Financial Court was established in 2018 as a specialized financial court. Under Xi, an increasing share of laws passed by the NPC explicitly affirmed the leadership of the CCP, with the share increasing from 4% in 2018 to nearly 70% in 2024.
Sources: en.wikipedia.org
=== Generation === Progestins in birth control pills are sometimes grouped by generation. While the 19-nortestosterone progestins are consistently grouped into generations, the pregnane progestins that are or have been used in birth control pills are typically omitted from such classifications or are grouped simply as "miscellaneous" or "pregnanes". In any case, CPA has been described as a "first-generation" progestin similarly to closely related progestins like chlormadinone acetate, medroxyprogesterone acetate, and megestrol acetate.
A further derivative of rasagiline, ladostigil ([N-propargyl-(3R)-aminoindan-5-yl]-N-propylcarbamate), a dual MAO-B inhibitor and acetylcholinesterase inhibitor, was developed for treatment of Alzheimer's disease and other conditions but was ultimately never introduced for medical use.
The Economist reports that China has become a "scientific superpower", citing numerous examples of its rapid development across a wide range of fields. 20 June – Following a surge in population of the Iberian lynx – from 62 mature individuals in 2001 to 648 in 2022 – the International Union for Conservation of Nature removes the animal from its "endangered" list, classing the animal as "vulnerable" instead. 24 June – The discovery of three Super-Earth candidates around HD 48948, a K-type dwarf star located 55 light-years away, is reported. One planet lies within the habitable zone. 25 June – China's Chang'e 6 lunar exploration mission successfully returns to Earth after taking rock and soil samples from the far side of the Moon. The orbiter proceeded on a mission to carry out observations at Sun-Earth Lagrange point L2 after dropping the sample off to Earth. Promising results of health and medical research are reported: a blood AI test of plasma proteins that predicts Parkinson's disease up to 7 years before symptom onset (18 June), walking programs as a cost-effective method against lower back pain recurrence (19 June). Hazard research is published: a study finds toxic metals including lead and arsenic in tampons (22 June), and a study indicates ocean water intrusion causing Antarctic ice-sheet grounding zones melting is a further tipping point in the climate system (25 June).
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.